TABLE 3.
Univariate regression analyses.
| LV MEEi improvement |
||
| Regression coefficient | P-value | |
| Age | 0.99 | <0.0001 |
| Female sex | 1.07 | 0.202 |
| Mean systolic BP during Follow-up (mmHg) | 0.99 | 0.378 |
| Mean diastolic BP during Follow-up (mmHg) | 1.00 | 0.439 |
| Mean pulse pressure (mmHg) | 1.00 | 0.949 |
| Mean heart rate during follow-up (bpm) | 0.99 | 0.793 |
| Smoke habits (%) | 0.94 | 0.361 |
| Obesity (%) | 0.87 | 0.034 |
| Diabetes (%) | 0.72 | 0.001 |
| Mean body mass index during follow up (kg/m2) | 0.99 | 0.024 |
| Mean weight during follow up (kg) | 0.99 | 0.003 |
| Weight loss (%) | 1.13 | 0.081 |
| Mean Fasting plasma glucose during follow up (mg/dl) | 1.00 | 0.005 |
| Mean serum uric acid during follow up (mg/dl) | 1.00 | 0.833 |
| Mean serum Triglycerides during follow up (mg/dl) | 1.00 | 0.006 |
| Mean serum total cholesterol during follow up (mg/dl) | 1.00 | 0.859 |
| Mean serum HDL cholesterol during follow up (mg/dl) | 1.01 | 0.001 |
| Mean METS-IR | 0.99 | <0.0001 |
| Mean CKD-EPI during follow up | 1.00 | 0.078 |
| LV mass index reduction at the end of follow up (g/m2.7) | 2.72 | <0.0001 |
| Number of medications in at least 50% of control visits | 1.00 | 0.921 |
| Anti-renin-angiotensin-aldosterone system | 0.97 | 0.614 |
| Antiplatelet therapy | 0.84 | 0.027 |
| Dihydropyridine calcium channel blockers | 0.81 | 0.002 |
| Beta-blockers | 1.52 | <0.0001 |
| Statins | 1.05 | 0.504 |
| Diuretics | 0.98 | 0.777 |
BP, blood pressure; CKD-EPI, chronic kidney disease epidemiology collaboration; LV, left ventricular; LV EF, left ventricular ejection fraction; MEEi, mechano-energetic efficiency indexed for myocardial mass.